Mode
Text Size
Log in / Sign up

Registry study links ARNI therapy groups to divergent mortality and hospitalization risks in HFrEF patientsYour Heart's Upper Chamber Holds the Key to Survival

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that ARNI therapy group associations with mortality and hospitalization were observed in an observational registry study.

This multicenter STRATS-HF-ARNI registry study evaluated the prognostic implications of ARNI-based therapy in 1,182 patients with HFrEF over a one-year follow-up period. The analysis focused on all-cause mortality, cardiovascular mortality, and HF hospitalization as primary outcomes, stratifying patients into distinct groups based on concurrent assessment of LV and LA strain metrics.

Results indicated that Group B was associated with significantly higher risks of all-cause mortality (aHR 3.53; 95% CI 1.60-7.79) and cardiovascular mortality (aHR 5.68; 95% CI 1.91-16.92) compared to Group A. Additionally, Group C demonstrated a higher risk of HF hospitalization (aHR 2.25; 95% CI 1.31-3.86) relative to Group A. The study did not report specific adverse events, discontinuations, or tolerability data.

The authors note that concurrent assessment of LV and LA strain may provide incremental prognostic value beyond LV-centric metrics alone. However, because this is an observational cohort study, the reported associations cannot be interpreted as causal. The authors caution against generalizing these findings beyond the specific registry population.

The Hidden Danger in a Healing Heart

Imagine your heart is a two-story house. The downstairs room pumps blood to the rest of the body. The upstairs room fills that room with blood before it pumps. For years, doctors only checked the downstairs room. They assumed that if the downstairs room got better, the whole house was safe.

But that upstairs room matters just as much. It acts like a pressure valve. If it gets stiff or weak, it cannot push blood down properly. This causes the downstairs room to work harder and fail sooner.

Heart failure is common. Millions of people live with it every day. The main goal of treatment is to make the heart pump better. New medicines called ARNI drugs are very good at fixing the lower chamber.

However, many patients still face serious risks. They might feel better, but something else is wrong. Current tests often miss this hidden problem. Doctors see a healthy lower heart but do not see the struggling upper heart. This leaves patients vulnerable to sudden crashes or hospital stays.

In the past, doctors looked only at the left ventricle. They called this the "ventricular-centric" view. If the ventricle got bigger or squeezed better, they celebrated. They thought the patient was on the road to recovery.

But here's the twist. This study shows that looking only at the ventricle is like judging a car by its engine while ignoring the brakes. You can have a strong engine, but if the brakes fail, the car stops safely. The same is true for the heart.

Think of the heart chambers like a relay race. The upper chamber passes the baton to the lower chamber. If the upper chamber is weak, the lower chamber has to run twice as hard to get the job done.

This extra work causes damage over time. The lower chamber eventually gets tired too. By the time the lower chamber fails, the patient is in crisis. Checking both chambers is like watching both runners. If one stumbles, the team loses.

Researchers looked at data from over 1,100 patients. These people had heart failure and took ARNI drugs. They had heart scans at the start and again after one year.

The team sorted patients into four groups based on how their heart chambers changed. One group had a lower chamber that improved but an upper chamber that got worse. This group faced the highest danger.

The most important finding is about that specific group. Even though their lower heart got stronger, their upper heart got weaker. This mismatch was a huge red flag.

Patients in this group were 3.5 times more likely to die from any cause. They were also 5.7 times more likely to die from heart problems. This risk was just as bad as patients whose lower heart never improved at all.

But there's a catch.

This does not mean the medicine failed. The medicine worked on the lower heart. The problem was that the upper heart did not keep up. This hidden issue was invisible to standard tests.

This research fits into a bigger picture. Doctors are realizing that the heart is a complex machine. Fixing one part is not enough. We need to understand how all parts work together.

This finding suggests that future heart scans should check both chambers. It helps doctors spot danger early. Early spotting means better plans for patients. It means catching problems before they become emergencies.

If you or a loved one has heart failure, talk to your doctor about heart scans. Ask if they check both the top and bottom chambers. Knowing the full picture helps you make smarter choices.

Do not stop your medicine because of this news. These drugs are still vital. But knowing the full story helps your doctor adjust your care plan. You might need extra monitoring or different lifestyle changes.

This study is important, but it has limits. It looked at patients in a registry, which is a specific group. The results might look different in other hospitals. Also, this is new science. We do not have a new test ready yet.

Doctors are working on new ways to measure both chambers easily. They hope to put this into routine care soon. Until then, patients should stay on their current treatment plans.

Research takes time. We need to prove this works in many different places. Then, we can change how we treat everyone. Stay hopeful. Science is moving forward to keep you safer.

Study Details

Sample sizen = 1,182
EvidenceLevel 5
PublishedApr 2026
View Original Abstract ↓
Aims: Assessment of treatment response in HFrEF has largely relied on left ventricular (LV)-centric parameters, yet the left atrium (LA) plays a central role in modulating LV filling and reflects the cumulative hemodynamic burden. Whether discordant recovery between LV and LA function carries distinct prognostic implications in patients treated with ARNI-based therapy remains unknown. Methods and results: From the multicenter STRATS-HF-ARNI registry, 1,182 patients with HFrEF who underwent serial echocardiography at baseline and one-year follow-up were included. Patients were classified into four strain recovery phenotypes according to the direction of change in LVGLS and LASr at one year: Group A, concordant recovery (57.4%); Group B, discordant atrial non-recovery (11.2%); Group C, discordant ventricular non-recovery (15.6%); and Group D, concordant non-recovery (16.0%). Clinical outcomes included all-cause mortality, cardiovascular mortality, and HF hospitalization. Despite achieving LV functional improvement, Group B exhibited persistent LASr deterioration, accompanied by less favorable hemodynamic trajectories compared with Group A. On multivariable Cox regression, Group B was associated with significantly higher risks of all-cause mortality (adjusted hazard ratio [aHR] 3.53, 95% confidence interval [CI] 1.60-7.79) and cardiovascular mortality (aHR 5.68, 95% CI 1.91-16.92), comparable to Group D. Group C demonstrated higher HF hospitalization risk (aHR 2.25, 95% CI 1.31-3.86). The adverse prognostic impact of discordant atrial non-recovery was consistently observed across subgroups stratified by baseline LVGLS and LASr levels. Conclusion: In HFrEF patients treated with ARNI-based therapy, persistent LA dysfunction despite LV functional improvement identifies a high-risk phenotype comparable to concordant non-recovery. These findings suggest that concurrent assessment of LV and LA strain may provide incremental prognostic value beyond LV-centric metrics alone.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.